Quicksilver Scientific

Free Shipping on Orders over $50 (Excludes PR)
0
0
Subtotal: $0.00

No products in the cart.

Milk Thistle References

  1. Abenavoli L, et al. Milk thistle in liver diseases: Past, present, future. Phytother Res. 2010; 24(10): 1423-1432.
  2. Gu X, et al. Molecular mechanisms underlying chemical liver injury. Expert Rev Mol Med. 2012; 14: e4.
  3. Gerber LH, et al. Importance of fatigue and its measurement in chronic liver disease. World J Gastroenterol. 2019; 25(28): 3669-3683.
  4. Acharya C, Bajaj J. Gut microbiota and complications of liver disease. Gastroenterol Clin North Am. 2017; 46(1): 155-169.
  5. Crocenzi FA, et al. Effect of silymarin on biliary bile salt secretion in the rat. Biochem Pharmacol. 2000; 59(8): 1015-1022.
  6. Karimi G, et al. “Silymarin”, a promising pharmacological agent for treatment of diseases. Iran J Basic Med Sci. 2011; 14(4): 308-317.
  7. Pradhan SC, Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J Med Res. 2006; 124(5): 491-504.
  8. Dixit N, et al. Silymarin: A review of pharmacological aspects and bioavailability enhancement approaches. Indian J Pharmacol. 2007; 39(4): 172-179.
  9. Vargas-Mendoza N, et al. Hepatoprotective effect of silymarin. World J Hepatol. 2014; 6(3): 144-149.
  10. Surai PF. Silymarin as a natural antioxidant: An overview of the current evidence and perspectives. Antioxidants (Basel). 2015; 4(1): 204-247.
  11. Kim EJ, et al. Silymarin inhibits morphological changes in LPS-stimulated macrophages by blocking the NF-κB pathway. Korean J Physiol Pharmacol. 2015; 19(3): 211-218.
  12. Lovelace ES, et al. Silymarin suppresses cellular inflammation by inducing reparative stress signaling. J Nat Prod. 2015; 78(8): 1990-2000.
  13. Esmaeil N, et al. Silymarin impacts on immune system as an immunomodulator: One key for many locks. Int Immunopharmacol. 2017; 50: 194-201.
  14. Choi YH and Yan GH. Silibinin attenuates mast cell-mediated anaphylaxis-like reactions. Biol Pharm Bull. 2009; 32(5): 868-875.
  15. Liu CH, et al. Antiviral activities of silymarin and derivatives. Molecules. 2019; 24(8): 1552.
  16. de Oliveira DR, et al. In vitro antimicrobial and modulatory activity of the natural products silymarin and silibinin. Biomed Res Int. 2015; 2015: 292797.
  17. Federico A, et al. Silymarin/silybin and chronic liver disease: A marriage of many years. Molecules. 2017; 22(2): 191.
  18. El-Lakkany NM, et al. Anti-inflammatory/anti-fibrotic effects of the hepatoprotective silymarin and the schistosomicide praziquantel against Schistosoma mansoni-induced liver fibrosis. Parasit Vectors. 2012; 5: 9.
  19. Perez-Sanchez A, et al. Intestinal permeability study of clinically relevant formulations of Silibinin in Caco-2 Cell monolayers. Int J Mol Sci. 2019; 20(7): 1606.
  20. Kumar N, et al. Silymarin liposomes improves oral bioavailability of silybin besides targeting hepatocytes, and immune Cells. Pharmacol Rep. 2014; 66(5): 788-798.
  21. Ahn H, et al. Liposomal delivery systems for intestinal lymphatic drug transport. Biomater Res. 2016; 20: 36.
  22. Alyautdin R, et al. Nanoscale drug delivery systems and the blood-brain barrier. Int J Nanomedicine. 2014; 9: 795-811.
  23. Spector AA, et al. Membrane lipid composition and cellular function. J Lipid Res. 1985; 26(9): 1015-1035.
0
    0
    Your Cart
    Your cart is empty
      Calculate Shipping
      Apply Coupon